KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
|Recent News||More >>|
KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
KemPharm, Inc. Provides Corporate and Clinical Update
KemPharm to Present Data at PAINWeek 2016
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|